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Abstract
Background: Diagnosis and follow‐up of respiratory diseases traditionally rely on
pulmonary function tests (PFTs), which are currently performed in hospitals and
require trained personnel. Smartphone‐connected spirometers, like the Air Next
spirometer, have been developed to aid in the home monitoring of patients with
pulmonary disease. The aim of this study was to investigate the technical validity
and usability of the Air Next spirometer in pediatric patients.
Methods: Device variability was tested with a calibrated syringe. About 90 subjects,
aged 6 to 16, were included in a prospective cohort study. Fifty‐eight subjects
performed conventional spirometry and subsequent Air Next spirometry. The bias and
the limits of agreement between the measurements were calculated. Furthermore,
subjects used the device for 28 days at home and completed a subject‐satisfaction
questionnaire at the end of the study period.
Results: Interdevice variability was 2.8% and intradevice variability was 0.9%. The
average difference between the Air Next and conventional spirometry was 40mL for
forced expiratory volume in 1 second (FEV1) and 3mL for forced vital capacity (FVC).
The limits of agreement were −270mL and +352mL for FEV1 and −403 mL and
+397mL for FVC. About 45% of FEV1 measurements and 41% of FVC measurements
at home were acceptable and reproducible according to American Thoracic Society/
European Respiratory Society criteria. Parents scored difficulty, usefulness, and
reliability of the device 1.9, 3.5, and 3.8 out of 5, respectively.
Conclusion: The Air Next device shows validity for the measurement of FEV1 and
FVC in a pediatric patient population.
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1 | INTRODUCTION
Diagnosis and longitudinal follow‐up of pulmonary diseases have
relied on pulmonary function tests (PFTs) since the nineteenth
century.1 Traditionally conducted in the clinic, spirometry can be a
difficult technique, and the accuracy and repeatability depend on
many factors such as equipment, patient effort, and supervision and
encouragement of a technician. Nevertheless, a single PFT is no more
than a snapshot of disease activity, and is unable to capture the
variability of symptoms in chronic pulmonary disease.
Longitudinal data on a regular basis regarding pulmonary health
could be very valuable for patients, clinicians, and clinical researchers,
and this could be obtained by performing PFTs at the patients' home.
An increase in readily available objective longitudinal data could be
particularly useful in pediatrics, as children often find it difficult to
perceive and express the severity of their symptoms.2,3
Researchers have investigated the clinical value of home‐based
measurements of several devices for pediatric asthma and cystic fi-
brosis (CF). While pulmonary outcomes were correlated to disease
activity,4 the devices appeared to offer little benefit for clinical
practice in terms of reduced admission rates, better disease control,
or slower decline in pulmonary function.5‐7 Since then, improvements
in technology have allowed for the development of devices for
measurement of complete flow‐volume curves at relatively low cost.
An example is the Air Next spirometer, a Bluetooth connected de-
vice, allowing patients to perform spirometry tests with a smart-
phone. Use of the device has been reported in adult patients, but not
yet in the pediatric population.8,9 Before implementation in pediatric
clinical care or clinical trials, a comprehensive technical validation of
the device must be performed, consisting of the assessment of intra‐
and interdevice variability, comparison with conventional spirometry,
as well as the assessment of usability for pediatric patients.
The aim of this study is to determine the agreement between the
Air Next spirometer and conventional spirometry and to evaluate the
usability of the device for children and parents when used at home.
2 | MATERIALS AND METHODS
2.1 | Location and ethics
This study was conducted at the Juliana Children's Hospital (HAGA
teaching hospital, The Hague, The Netherlands) and Sophia Children's
Hospital (Erasmus Medical Centre, Rotterdam, The Netherlands) from
November 2018 to January 2020. The study protocol was reviewed
and approved by the Medical Ethics Committee, Zuidwest Holland
(The Hague, The Netherlands) before initiation of the study. The study
was conducted according to the Dutch Act on Medical Research
Involving Human Subjects (WMO) and in compliance with Good
Clinical Practice. Written informed consent was obtained from all
parents and children aged 12 years and older. Assent was obtained
from children aged younger than 12. The trial was registered at the
Dutch Trial Registry (NTR, Trial NL7611).
2.2 | Subjects and study design
This analysis was part of a study investigating a novel home‐
monitoring platform (CHDR MORE) in pediatrics. During this study,
pediatric patients with controlled asthma (n = 30), uncontrolled
asthma (n = 30), and CF (n = 30) were recruited from the outpatient
clinic of the hospitals. All children were aged between 6 and 16 years.
Asthma control was defined using the Global Initiative for Asthma
criteria and Asthma Control Questionnaire (cutoff > 1.5 points).10,11
Children and parents were given a 10‐minute training and practice
session and were asked to perform PFTs once daily with the mobile
device for a duration of 28 days. When logistically feasible, children
visited the hospital to perform a conventional spirometry test at the
outpatient clinic at the beginning or end of the study period and
performed an Air Next spirometry test during the same visit. The
sequence of tests was chosen based on preference for each patient.
2.3 | Spirometry
Conventional spirometry was performed on a MasterScreen PFT
(Vyaire, Mettawa, IL) at the Juliana Children's Hospital and the Sophia
Children's Hospital, calibrated according to American Thoracic Society
(ATS)/European Respiratory Society (ERS) guidelines. Home‐based
spirometry was performed using the Air Next spirometry device
(NuvoAir, Stockholm, Sweden). The device employs a turbine mechan-
ism with disposable mouthpieces and cannot be calibrated by the user.
The device uses Bluetooth to connect to a smartphone. Motorola G6
(Motorola, Chicago, IL) phones were used during the study. An accom-
panying application was installed, which uses age, sex, and height to
calculate reference values according to the Global Lung Function
Initiative 2012 equations,12 and requires Android 5.0 or higher. The
application provides the forced expiratory volume in 1 second (FEV1),
forced vital capacity (FVC), FEV1/FVC ratio, and peak expiratory flow
(PEF) per maneuver.
2.4 | Device variability
The Air Next device cannot be manually calibrated. We used a cali-
brated syringe (Viasys, Conshohocken, PA) with a capacity of
2994mL to evaluate accuracy and the inter‐ and intradevice varia-
bility. The syringe was used to push the complete capacity through an
Air Next device 20 times per device on 20 devices with a single
turbine. In addition, the syringe was used on 25 different turbines
with a single Air Next device.
2.5 | Test procedures
ATS and ERS acceptability guidelines were used to judge and grade
PFT quality (grade A‐F from best to worst).13 Spirometry maneuvers
were acceptable if the start was rapid and without hesitation, the
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course of the expiratory maneuver was continuous, without any ar-
tefacts or evidence of coughing in the first second and if the end of
the maneuver did not show early or abrupt interruption. The dif-
ference between the best two acceptable FVC and FEV1 should have
been less than 150mL. At least three maneuvers were performed per
spirometry session. When it was difficult to obtain reproducible
maneuvers during supervised measurements, a maximum of 10
maneuvers per patient were performed and the usable maneuvers
were used. For home use, subjects were instructed to perform three
maneuvers per session and were able to perform two additional
measurements when appropriate (for example, mistiming of the
forced exhalation or application errors). Subjects were not asked to
self‐grade repeatability during the study period.
2.6 | End‐of‐study questionnaire
At the end of the study period, a questionnaire regarding user ex-
perience was completed. Parents and participants were asked to give
their opinion about the reliability of the device, the difficulty of using
the device, and whether they found the use of the device to be useful
or tedious on a 5‐point Likert scale.
2.7 | Statistics
Baseline characteristics were summarized. Inter‐, intra‐, and turbine
variability were calculated and expressed as a coefficient of varia-
bility (CV). Concordance between Air Next spirometry and conven-
tional spirometry was assessed using the methods described by
Altman and Bland.14 The mean differences between methods and the
95% limits of agreement were calculated for FEV1, FVC, PEF, and FEV1/
FVC ratio. For FEV1 and FVC, acceptable bias was no more than 100mL.
For PEF and FEV1/FVC ratio, the acceptable average bias was 300mL/s
and 10%, respectively.13,15 Pearson correlation coefficients between the
two methods were calculated. Spirometry measurements at home were
graded for quality and the number of maneuvers assigned to each grade
were summarized descriptively. A mean grade per subject was calculated.
The average mean grades of the three study groups were compared via a
one‐way analysis of variance test and pairs were compared with Tukey's
range test to adjust for multiple comparisons. Usability was evaluated by
analyzing the end‐of‐study questionnaire completed by subjects and their
parents. R version 3.5.1 was used for statistical analysis and visualization.
Promasys software (OmniComm, Lauderdale, FL) was used for data
management.
3 | RESULTS
3.1 | Baseline characteristics
A total of 90 subjects were included in the main study. The average
age was 10 years (range, 6‐15). Subjects had performed an average of
12 (SD 11) hospital‐based PFTs before the study. Other baseline
characteristics are displayed in Table 1.
3.2 | Device variability
Of 400 measurements in 20 devices, the average bias from the ca-
librated 2994mL was −40 mL (range, −124 to 56mL). The average
intradevice CV was 0.9% (range, 0.6%‐1.2%). Furthermore, the
average interdevice CV was 2.8%. Average turbine bias was −70 mL
and turbine CV was 1.8%. About 4% of measurements with the
calibrated syringe exceeded the 3% accuracy threshold advised by
ATS standards.
3.3 | Measurement validity
Fifty‐eight subjects were able to perform hospital and Air Next PFTs
subsequently. When comparing output between the two methods,
there was one extreme outlier, most likely due to a technical defect
resulting in a blockage of the outflow of the Air Next turbine, which
was excluded from the statistical analysis. Figure 1 shows the limits
of agreement and correlation between the Air Next and conventional
spirometry of the several parameters. For FEV1, the average bias
was 40mL and the 95% limits of agreement were −270 and +352mL.
The Pearson correlation coefficient (R) was .97 (P < .001). The bias of
TABLE 1 Baseline characteristics
All
participants (n = 90)
Comparison
participantsa (n = 58)
Age, mean (SD) 10.2 (2.7) 10.2 (2.7)
Sex
Male, n (%) 54 (60) 37 (65)




30 (33.3) 27 (47)
Uncontrolled asthma,
n (%)
30 (33.3) 23 (40)
Cystic fibrosis, n (%) 30 (33.3) 7 (12)
Weight, kg, mean (SD) 39.5 (15.9) 40.8 (16.2)
Body mass index (SDS),
mean (SD)
0.6 (1.4) 0.8 (1.4)
Height, cm, mean (SD) 144.1 (16.6) 144 (15.5)
Ethnicity
Caucasian, n (%) 69 (77) 37 (74)
Other, n (%) 21 (23) 15 (26)
Spirometry experience,
n (SD)
12.2 (11) 8.4 (8)
Abbreviation: SDS, standard deviation score.
aComparison participants: patients who also performed conventional
spirometry at the beginning or the end of the study period.
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F IGURE 1 Concordance between Air Next and conventional spirometry. A, C, E, and G, Bland‐Altman plots displaying the differences
between conventional spirometry and Air Next spirometry against the averages of the two techniques for FEV1, FVC, FEV1/FVC ratio, and PEF,
respectively. Dotted lines reflect the average bias (middle line) and the 95% limits of agreement (outer lines). B, D, F, and H, Pearson correlation
between the two measurements. FEV1, forced expiratory volume in 1 second, FVC, forced vital capacity; PEF, peak expiratory flow
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FVC was 3mL with limits of agreement of −403mL and +397mL
(R = .97, P < .001). Furthermore, the analysis of PEF demonstrated an
average difference of 590mL/s (95% limits of agreement of −500mL
and 1690mL) and the average difference for the FEV1/FVC ratio was
0.6% (95% limits of agreement of −5.8% and 7.0%). Although the
correlation coefficient was lower as compared with FEV1 and FVC,
there was still a good correlation between the two methods for both
PEF (R = .93, P < .001)) and FEV1/FVC ratio (R = .91, P < .001). There
was no proportional bias for any of the parameters. There was a
correlation (R = −.33, P = .01 for FEV1 and R = −.26, P = .05 for FVC)
between the absolute difference in FEV1 and FVC (expressed in % of
predicted FEV1 and FVC) and age (Figure S1), but not between the
absolute difference and previous spirometry experience, expressed
as the amount of PFTs performed in the past (Figure S2). There was
no statistically significant difference in absolute bias for FEV1
between the three groups (P = .28; Figure S3). When the absolute
difference between the two methods was expressed as a percentage
of the predicted FEV1 and FVC, the mean bias was 6.3% (SD 5%) of
predicted FEV1 and 6.7% (SD 5.7%) of predicted FVC. The bias of
FEV1 of subjects who performed the comparison at the end of the
study period was slightly higher (3% of predicted, P = .009) compared
to subjects who performed the comparison at the beginning of the
study period (Figure S4).
3.4 | Technique and day‐to‐day variability
A total of 2047 spirometry measurements were performed with the
Air Next device during the course of the study, resulting in an
average compliance of 78%. The curves of 1821 sessions were
available for analysis. When graded according to the ATS/ERS
criteria, 45% of the FEV1 measurements were considered acceptable
and reproducible, as well as 41% of the FVC measurements. A
significant number of sessions were grade E, meaning they did not
produce more than one acceptable maneuver or that the reprodu-
cibility was too low. About 2% of measurements were neither
acceptable nor usable for both FEV1 and FVC. Summarized grades
are listed in Figure 2A,B. There was a statistically significant
difference on average grade between CF patients and patients
with uncontrolled asthma (FEV1, P = .02; Figure 2C and FVC, P = .03;
Figure 2D). Age and average grade were not correlated (Figure S5).
Day‐to‐day CV of acceptable trials (grade A‐C) was 9.0% (SD 5.7%)
for FEV1 and 7.7% (SD 5.4%) for FVC.
3.5 | Usability
Sixty‐nine (77%) subjects completed the end‐of‐study questionnaire.
In general, parents found the use of the spirometry device to be
acceptable. When asked to score their agreement with the statement
“I found the use of the spirometer to be tedious,” the average score
was 1.8 out of 5 (SD 1.1). Furthermore, parents scored the difficulty
1.9 out of 5 (SD 1.2), usefulness 3.5 out of 5 (SD 0.9) and the
perceived reliability 3.3 out of 5 (SD 1.0). Summarized results are
displayed in Figure S6.
4 | DISCUSSION
The current study investigates the technical validity and user
experience of the Air Next spirometer for pediatric patients. Air
Next spirometer output was compared with the gold standard:
conventional spirometry in the clinic. Subjects and their parents also
completed a questionnaire regarding the usability of the device.
The interdevice, intradevice, and turbine variability were as-
sessed with a calibrated syringe of 2994mL. All of the measurements
were within 125mL of the reference. Although 125mL exceeds the
3% accuracy standard advised by the ATS, 96% of measurements fell
within the 3% range. The coefficients of variability were all below 3%,
which suggests that the repeatability of the device is good.
Bland‐Altman plots displaying the difference between the Air Next
measurements and conventional spirometry demonstrated a negligible
bias for FEV1, FVC, and FEV1/FVC ratio of 40mL, 3mL, and 0.6%, re-
spectively. Furthermore, the 95% limits of agreement for FEV1 and FVC
are comparable with earlier studies in adults.8,9 Both FEV1/FVC ratio and
PEF showed relatively wide limits of agreement compared with con-
ventional spirometry, while PEF demonstrated bias compared with the
gold standard. Interestingly, concordance of PEF was not reported in
earlier publications. While the grades of the supervised spirometry ses-
sions with the Air Next were all adequate (A‐C) according to ATS/ERS
criteria, we suspect the individual differences of FEV1 and FVC mea-
surements, and the consistently lower PEF of the Air Next measurements
to be mainly due to differences in technique. Subjects had to coordinate
several actions in quick succession: initiating the smartphone application,
complete a full forced inspiration, perform a controlled arm movement
towards the mouth, and finally complete a forced expiration. This is a
relatively complex sequence of actions compared with conventional su-
pervised spirometry and could influence the maximum effort given to the
forced expiration. The complexity of the sequence of actions may also
explain the correlation between absolute difference in FEV1 and age. For
most subjects, the spirometry session for comparison was the first time
they used the Air Next device. However, more familiarity with the
technique did not appear to lead to better concordance, considering the
observation that children who performed the comparison at the end of
the study period did not exhibit a smaller deviation from conventional
spirometry. We hypothesize this may be due to a decrease in motivation
in children who performed daily PFTs during the preceding 28 days.
Another important difference that may explain discordance is that small
devices exert low resistance to expiration in comparison with conven-
tional devices, which may affect the way children perform PFTs. While
the bias of 0.59 L casts doubt on the absolute accuracy of the device for
PEF measurements, the FVC, FEV1/FVC ratio, and especially FEV1 are
considered to be more important parameters of pulmonary health.16
Furthermore, the measured PEF may show good correlation with
symptom severity in the case of home monitoring. The limits of agree-
ment for FEV1 and FVC are wider than the bias of the Air Next device
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determined with the calibrated syringe. This suggests that individual
differences between the Air Next and conventional spirometry are the
result of bias by both the patient and the device. A subgroup analysis of
25 children who displayed good technique in the home setting (median
grade A‐B) showed slightly smaller limits of agreement. (Figure S7). Limits
of agreement of this magnitude are inherent to direct comparisons of
spirometers, as demonstrated by the literature on this subject.17‐20 Still,
the relevance of the individual differences of this magnitude is higher in
pediatrics, because their smaller expected lung volumes lead to biases
that may be clinically relevant.
F IGURE 2 ERS/ATS grades for measurements performed at home. All spirometry sessions were graded according to ATS/ERS guidelines for
FEV1 and FVC separately. Grade A‐E represent sessions with acceptable maneuvers but with varying repeatability. Grade U includes session with
usable but not with acceptable maneuvers and grade F is reserved for session without acceptable or usable maneuvers. A, Proportion of spirometry
sessions that were awarded each grade for FEV1. B, Proportion of spirometry sessions that were awarded each grade for FVC. C, Boxplot of average
FEV1 grade per study group. Dots represent individual averages. There was a statistically significant difference between the CF and uncontrolled
asthma group (P = .02). D, Boxplot of average FVC grade per study group. Dots represent individual averages. There was a statistically significant
difference between the CF and uncontrolled asthma group (P = .03). ATS, American Thoracic Society; CF, cystic fibrosis; ERS, European Respiratory
Society; FEV1, forced expiratory volume in 1 second, FVC, forced vital capacity [Color figure can be viewed at wileyonlinelibrary.com]
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Subjects used the device at home for 28 consecutive days in the
main study. Individual curves were assessed and graded according to
the ERS/ATS criteria. The majority of measurements would be con-
sidered suitable for further analysis, but 36% of FEV1 measurements
and 39% of FVC measurements were graded D, E, U, or F, meaning
that they were not performed technically adequate.21 Interestingly,
patients with uncontrolled asthma appeared to exhibit worse tech-
nique than patients with CF. A number of sessions with poor tech-
nique could have been the result of dyspnea due to the underlying
disease, and the obtained values for FEV1, FVC, and PEF could still
correlate well with perceived symptoms. However, the difference in
technique could also be explained by the fact that children with CF
perform a PFT every 3 months, which results in more familiarity with
the technique. Therefore, this observation could also indicate a need
for more training sessions, which has been reported to be beneficial
for improving inhalation technique.22 Extensive training could
be beneficial for home‐based spirometry as well and could be in-
vestigated further during a clinical validation study. Although
the acceptability criteria that were the cause of a maneuver being
unacceptable were not routinely recorded, the unacceptable man-
euvers most often did not reach the end of forced expiration criteria.
A high back‐extrapolation volume was encountered often as well.
Both are indicators of insufficient effort during the end and start of
the maneuver, respectively.13
According to the end‐of‐study questionnaire, parents and chil-
dren did not find the measurements to be difficult, although this
assessment may change when immediate feedback on the quality of
the measurements is provided. During the study, some participants
had recurrent Bluetooth connectivity problems, which may be re-
lated to the used phone or the particular device that was used. To
optimize reliability and usability, more intensive training and strict
instructions may be necessary. During this study, participants un-
derwent a 10‐minute training, which may not be enough to prevent
wrong conduct. Still, issues such as low motivation, technological
glitches, or even something as trivial as blocking air inflow with the
tongue or air outflow with the hands are difficult to avoid completely
without the supervision of a trained technician. This was demon-
strated by the extreme outlier excluded in our analysis. Issues such as
these may cause false positive or false negative results when used for
the remote diagnosis of pulmonary obstruction.
Nevertheless, when correctly performed, the Air Next demon-
strates reliability for FEV1 and FVC measurements compared with
conventional spirometry and with a good user experience. In clinical
care, the device could support home monitoring and provide timely
information to patients when to contact a doctor. Furthermore, the
device can be used for the purpose of telemedicine, which may be
increasingly used during and after the crisis precipitated by the
coronavirus disease‐2019 pandemic. Although previous studies
indicating home‐based spirometry does not add value to pediatric
clinical care, this may change when combined with other assessments,
such as a symptom questionnaire,23 a wearable device, or other
monitoring techniques.24 This may help physicians to improve mon-
itoring of pediatric patients, while reducing the burden of disease.
In addition, with the increasing popularity of digital endpoints and
decentralized clinical trials, the device could play an important role in
future clinical trials for pediatric CF, asthma, and other pulmonary
diseases, which could decrease the burden of clinical trial participation.
Finally, the device may be useful for primary care physicians without
access to conventional spirometers in low‐income countries or rural
areas, or at the point of care in patients' homes.
This study has some limitations, one of which is that not all of the
participants could be included in the validation group. This is mainly
due to logistical reasons and the fact that the comparison was part of a
secondary analysis of a clinical study. However, there were no large
differences in baseline characteristics between the complete cohort
and the validation cohort (Table 1). The nonrandomized order of tests
may have influenced the results through spirometry‐induced bronch-
oconstriction.25 However, we did not diagnose this condition in any
of the included subjects. The curves of 226 spirometry sessions
were unavailable for review due to application connectivity errors.
However, this issue occurred at random and, therefore, did not impact
our overall conclusions. Although we found no correlation between
the absolute bias and previous spirometry experience when comparing
conventional spirometry to the Air Next, the proportion of highly
experienced subjects was low. A higher number of experienced sub-
jects may have resulted in a better correlation. A strength of the study
is the inclusion of pediatric patients with controlled asthma, un-
controlled asthma, and CF, giving a representative sample of possible
pediatric target populations. The manufacturer has unlocked addi-
tional functions of the device since the initiation of this study, allowing
for the measurement of the inspiratory measurements forced in-
spiratory vital capacity, peak inspiratory flow, maximal inspiratory
flow, and maximum expiratory flow. These functionalities should be
independently validated before integration in clinical care or clinical
trials. Future clinical validation of home‐based measurements with
the Air Next will be performed to determine the objectivity and
reproducibility of longitudinal unsupervised measurements.
5 | CONCLUSION
The Air Next spirometer is technically valid for the measurement of
FEV1 and FVC in children aged 6 to 16, while PEF measurements
show significant bias. The user experience was considered favorable
by subjects and their parents. FEV1 and FVC measured at home
could add significant value to clinical care and clinical trials, but fu-
ture studies should determine the clinical value of home‐based
spirometry measurements for the purpose of monitoring disease‐
activity or response to treatment, possibly in combination with other
home‐based measurements.
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